• Breast Cancer
    • Norman Wolmark
    • Norman Wolmark: Influence Statistics

      Norman Wolmark

      Norman Wolmark

      Show email address

      NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA | NSABP/NRG Oncology, Pittsburgh, PA, USA | NRG Oncology and University of Pittsburgh, Pittsburgh, PA; | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Norman Wolmark:Expert Impact

      Concepts for whichNorman Wolmarkhas direct influence:Breast cancer,Adjuvant chemotherapy,Neoadjuvant chemotherapy,Colon cancer,Bowel project,Neoadjuvant therapy,Clinical trial,Radiation therapy.

      Norman Wolmark:KOL impact

      Concepts related to the work of other authors for whichfor which Norman Wolmark has influence:Breast cancer,Neoadjuvant chemotherapy,Lymph node,Ductal carcinoma,Radiation therapy,Estrogen receptor,Gene expression.

      KOL Resume for Norman Wolmark


      NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA

      University of Pittsburgh and NRG Oncology, Pittsburgh1, United States


      Allegheny General Hospital, Pittsburgh, Pennsylvania

      Department of Clinical Trials, Alleghany Health Networ k, Pittsburgh, PA, USA.

      NRG Oncology, Pittsburgh, PA


      NRG Oncology and the University of Pittsburgh , Pittsburgh, PA, USA

      Department of Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania

      University of Pittsburgh, Pittsburgh, PA.

      NSABP Foundation, Pittsburgh, PA


      National Surgical Adjuvant Breast and Bowel Project (NSABP), Nova Tower 2, 100 Allegheny Square, 15212, Pittsburgh, PA, USA

      See the Notes section for the full list of authors' affiliations.

      NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA;


      Department of Human Oncology, Allegheny Health Network Cancer Institute.

      National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA


      National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

      NSABP / NRG Oncology, and Allegheny Health Network Cancer Institute, Pittsburgh, PA

      Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania


      National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology, Pittsburgh, Pennsylvania

      NSABP/NRG Oncology, and The Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA;

      NRG Oncology and the Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA


      Section of Cancer Genetics and Prevention, Allegheny General Hospital, Pittsburgh, PA, USA

      NRG Oncology Pittsburgh and Philadelphia (NSABP is now part of NRG Oncology), Pittsburgh, PA


      National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Norman Wolmark is among the top experts in the world.
      Concept World rank
      cdkal1 pcr #1
      weekly trastuzumab lapatinib #1
      riskeligible women #1
      women chemoprevention #1
      fvl pt20210 mutations #1
      doxorubicin tac #1
      ibtr locoregional recurrence #1
      flox regimens #1
      independent predictors lrr #1
      limited axillary dissection #1
      cdx2positive tumors #1
      treatment arm amenorrhea #1
      negative adjuvant #1
      endometriosis endometrial hyperplasia #1
      flox study #1
      bcs breast #1
      93 xrt #1
      ser473 predicts benefit #1
      subset analyses #1
      analysis nsabp #1
      b‐10 #1
      findings diseasefree survival #1
      cycles fulv #1
      preop treatment groups #1
      patterns amplification #1
      patients nsabp #1
      doxorubicindocetaxel survival #1
      nsabp women #1
      treating postmenopausal #1
      trials combined analysis #1
      situ carcinoma mastectomy #1
      patients nar score #1
      surgery postoperative arm #1
      c‐01 #1
      ilrrs breast cancer #1
      bernard fisher #1
      sequential addition paclitaxel #1
      sphinctersaving resections #1
      8 years rfs #1
      segmental mastectomy radiation #1
      breast bowel #1
      349 her2 #1
      phase dose neratinib #1
      trials national #1
      fulv nsabp c07 #1
      bevacizumab antineoplastic agents #1
      pcr wp #1
      cyclophosphamide neoadjuvant #1
      status tamoxifen treatment #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Norman Wolmark

      KOL-Index: 29416

      BACKGROUND: Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or ...

      Known for Carboplatin Paclitaxel | Neoadjuvant Chemotherapy | 3 Trial | Negative Breast | Parp Inhibitor Veliparib
      KOL-Index: 24688

      CONTEXT: Among cancer-free women aged 35 years or older, tamoxifen reduced the incidence of estrogen receptor (ER)-positive but not ER-negative breast cancer. The effect of tamoxifen on breast cancer incidence among women at extremely high risk due to inherited BRCA1 or BRCA2 mutations is unknown.

      OBJECTIVE: To evaluate the effect of tamoxifen on incidence of breast cancer among cancer-free women with inherited BRCA1 or BRCA2 mutations.

      DESIGN, SETTING, AND PARTICIPANTS: Genomic analysis ...

      Known for Breast Cancer | Inherited Mutations | Women Brca1 | Tamoxifen Incidence | Prevention Trial
      KOL-Index: 23524

      BACKGROUND: In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axillary lymph node involvement. The findings indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease. However, questions arose about how long ...

      Known for Tamoxifen Therapy | 5 Years | Breast Cancer | Survival Disease | Positive Tumors
      KOL-Index: 22078

      BACKGROUND: Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.

      METHODS: The double-blind, randomised, phase 3 National Surgical Adjuvant Breast and Bowel Project (NSABP) ...

      Known for Ductal Carcinoma | Postmenopausal Women | Tamoxifen Anastrozole | Situ Lumpectomy | Phase 3
      KOL-Index: 21831

      CONTEXT: Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.

      OBJECTIVE: To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes.

      DESIGN, SETTING, AND PATIENTS: The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, ...

      Known for Raloxifene Tamoxifen | Invasive Breast | Nsabp Study | Thromboembolic Events | Uterine Cancer
      KOL-Index: 21799

      BACKGROUND: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients.

      METHODS: For this open-label, ...

      Known for Lapatinib Trastuzumab | Neoadjuvant Therapy | 3 Trial | Surgery Patients | Weekly Paclitaxel
      KOL-Index: 19600

      BACKGROUND: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which ...

      Known for Pathological Complete Response | Ypt0 Ypn0 Ypt0 | Pooled Analysis | Breast Chemotherapy | Surrogate Endpoint
      KOL-Index: 18640

      BACKGROUND: The finding of a decrease in contralateral breast cancer incidence following tamoxifen administration for adjuvant therapy led to the concept that the drug might play a role in breast cancer prevention. To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992.

      METHODS: Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age ...

      Known for Breast Cancer | Bowel Project | Risk Tamoxifen | National Surgical | Lobular Carcinoma Situ
      KOL-Index: 18182

      BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a ...

      Known for Docetaxel Capecitabine | Addition Bevacizumab | Doxorubicin Cyclophosphamide | Breast Cancer | Diseasefree Survival
      KOL-Index: 18045

      BACKGROUND: The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.

      METHODS: The study was done at 333 hospitals in North America. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast ...

      Known for Ductal Carcinoma | Tamoxifen Anastrozole | 5 Years | Sexual Functioning | Vaginal Symptoms
      KOL-Index: 18043

      In 1985 we presented results of a randomized trial involving 1843 women followed for five years that indicated that segmental breast resection (lumpectomy) followed by breast irradiation is appropriate therapy for patients with Stage I or II breast cancer (tumor size, less than or equal to 4 cm), provided that the margins of the resected specimens are free of tumor. Women with positive axillary nodes received adjuvant chemotherapy. Lumpectomy followed by irradiation resulted in a ...

      Known for Total Mastectomy | Breast Cancer | Lumpectomy Irradiation | Adjuvant Chemotherapy | Local Recurrence Tumor
      KOL-Index: 17979

      PURPOSE: Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.

      PATIENTS AND METHODS: National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel plus 52 weeks of trastuzumab beginning concurrently with paclitaxel in patients with ...

      Known for Cardiac Dysfunction | Adjuvant Therapy | Patients Trastuzumab | Cyclophosphamide Paclitaxel | Monoclonal Antibodies
      KOL-Index: 17615

      BACKGROUND: Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with ...

      Known for Breast Irradiation | Equivalence Trial | Patients Apbi | Accelerated Partial | Conserving Surgery
      KOL-Index: 17563

      BACKGROUND: Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND). The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether SLN resection in patients with breast cancer achieves the same survival and regional control as ALND, but with fewer side-effects.

      METHODS: NSABP B-32 was a randomised controlled phase 3 trial ...

      Known for Negative Patients | Breast Cancer | Regional Control | Sln Resection | Diseasefree Survival
      KOL-Index: 17516

      BACKGROUND: Tamoxifen reduces the risk for contralateral breast cancer by approximately 30%-50%, with benefits probably limited to women with estrogen receptor (ER)-positive primary disease. In a retrospective analysis of data from National Surgical and Adjuvant Breast and Bowel Project trials B-18, B-22, and B-25, we determined whether the ER status of primary breast cancer predicts the ER status of a subsequent contralateral breast cancer and whether tamoxifen treatment affects this ...

      Known for Contralateral Breast | Estrogen Receptor | Tamoxifen Patients | Primary Cancer | Hormonal Biomarkers

      Key People For Breast Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Gabriel N Hortobagyi
      breast cancer neoadjuvant chemotherapy estrogen receptors
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Charles M Perou
      breast cancer gene expression intrinsic subtypes
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      Jacques Ferlay
      cancer incidence global burden latin america

      NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA | NSABP/NRG Oncology, Pittsburgh, PA, USA | NRG Oncology and University of Pittsburgh, Pittsburgh, PA; | UPMC Hillman Cancer Center, Pittsburgh, PA, USA | NSABP/NRG Oncology, and Th

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.